Rosiglitazone-induced granulomatous hepatitis

Granulomatous hepatitis has many cause,,. Drugs are an important etiologic factor. Several oral hypoglycemic agents are available for treatment of type 11 diabetes. Rosiglitazone, a thiazolidinedione, is a newer agent in this class, It has not been shown to be hepatotoxic in the premarketing trials. However, a few case reports have implicated it as a cause of acute hepatocellular injury. The authors report a case of granulomatous hepatitis associated With use of rosiglitazone. Liver function tests should be done regularly to monitor patients on this medication.